AVLN ▲ +0.1% - Avalyn Pharma Inc. $AVLN - Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile Avalyn Pharma rose 0.1% following the publication of Phase 1 data for its lead candidate AP02, which demonstrated lung-targeted delivery capabilities and a favorable safety profile in early testing. The modest gain suggests investors viewed the clinical readout positively, though the data alone was insufficient to drive substantial momentum in early trading. 21-SEP-2026 09:00 AM ET